Table 2 Baseline characteristics, laboratory findings and diagnoses of the 80 patients participating the follow-up
ReA n = 31 | UA n = 16 | RA n = 15 | Other * n = 18 | P-value | |
|---|---|---|---|---|---|
Age, years, mean (range) SD | 30(9) | 40(13) | 40(12) | 37(11) | 0.010 |
Female, n (%) | 16(52) | 10(63) | 13(87) | 11(61) | 0.19 |
Onset of joint symptoms, n (%) acute subacute insidious | 21(68) 8 (26) 2 (6) | 9 (56) 2 (13) 5 (31) | 2 (14) 4 (29) 8 (57) | 10 (53) 5 (26) 4 (21) | 0.005 |
Size of affected joints, n (%) small large | 8 (27) 22 (73) | 7 (44) 9 (56) | 6 (43) 8 (57) | 8 (42) 11 (58) | 0.55 |
Type of arthritis, n (%) monoarthritis oligoarthritis polyarthritis | 3(10) 22 (76) 2 (7) | 1 (6) 9 (64) 3 (21) | 1(7) 2 (13) 10 (77) | 2(12) 10 (59) 5 (29) | < 0.001 |
Back pain, n (%) | 11(35) | 4(25) | 0(0) | 2(11) | 0.17 |
ESR mm/h, mean (SD) | 53(33) | 30(21) | 47(28) | 38(40) | 0.11 |
RF positive, n (%) | 1(3) | 1(6) | 5(33) | 2(12) | < 0.001 |
HLA–B27 positive, n (%) | 18(60) | 4(27) | 2(14) | 4(22) | 0.008 |
HLA–DR1 positive, n (%) | 7(27) | 4(29) | 3(20) | 6(40) | 0.66 |
HLA–DR4 positive, n (%) | 7(26) | 5(36) | 5(42) | 1(6) | 0.12 |
ASO positive, n (%) | 4(13) | 1(6) | 2(14) | 1(5) | 0.77 |
Chlamydia antibodies positive, n (%) | 10(32) | 1(6) | 2(14) | 2(11) | 0.13 |
Yersinia antibodies positive, n (%) | 5(16) | 0(0) | 0(0) | 0(0) | 0.062 |
Salmonella antibodies positive, n (%) | 2(7) | 0(0) | 0(0) | 0(0) | 0.66 |
Viral antibodies positive, n (%) | 1(3) | 1(6) | 0(0) | 3(22) | 0.096 |
Any positivity of infection, n (%) | 23(74) | 6(38) | 6(43) | 7(39) | 0.035 |